GC-001
Non-Small Cell Lung Cancer
PreclinicalActive
Key Facts
About Genocury Biotech
A Chinese biotech developing targeted gene therapies for oncology using advanced gene editing and delivery platforms.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CM24 | Purple Biotech | Phase 2 |
| Pepinemab (VX15/2503) | Vaccinex | Phase 1b/2 |
| Immunomodulator Platform | OmniCyte | Research |
| VisAcT (18F-AraG) Imaging in NSCLC | CellSight Technologies | Phase 2 |
| VNX-208 | Vironexis Biotherapeutics | Preclinical |
| AIC100 | AffyImmune Therapeutics | Pre-clinical/Planned |
| Lung (NSCLC) PD-L1 | Mindpeak | Commercial |
| Tiragolumab | Chugai Pharmaceutical | Phase III |
| SHR-1701 | Jiangsu Hengrui Medicine | Phase II/III |
| Acasunlimab (DuoBody-PD-L1x4-1BB) | Genmab | Phase 2/3 |
| VAC2 | Lineage Cell Therapeutics | Phase 1 |